BACKGROUND Previous trials showed promising antitumor activity and an acceptable safety profile associated with pembrolizumab in patients with early triple-negative breast cancer. Whether the addition of pembrolizumab to neoadjuvant chemotherapy would significantly increase the percentage of patient...
Research Assistant
AI chat, annotations, notes & similar papers
No comments yet
Be the first to share your thoughts!